Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: A report from the Children's Cancer Group

Medical and Pediatric Oncology

Volumn 27, Issue 6, 1996, Pages 505-514

  Feig, Stephen A ^a,l   Ames, Matthew M ^c   Sather, Harland N ^b   Steinherz, Laurel ^d   Reid, Joel M ^c   Trigg, Michael ^e   Pendergrass, Thomas W ^f   Warkentin, Phyllis ^g   Gerber, Mirjam ^h   Leonard, Marcia ^j   Bleyer, W Archie ^k   Harris, Richard E ⁱ  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MAYO CLINIC   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^f SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^h PFIZER INC   (United States)

ⁱ CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^j UNIVERSITY OF MICHIGAN   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l CHILDREN S ONCOLOGY GROUP   (United States)

more..

Author keywords

childhood acute lymphoblastic leukemia; daunomycin; idarubicin

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ASPARAGINASE; CYTARABINE; DAUNORUBICIN; IDARUBICIN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHILD; CHILD, PRESCHOOL; DAUNORUBICIN; DISEASE-FREE SURVIVAL; HUMANS; IDARUBICIN; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; PROGNOSIS; RECURRENCE;

EID: 10344263971     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199612)27:6<505::AID-MPO1>3.0.CO;2-P     Document Type: Article

References (43)

1. Reaman GH, Ladisch S, Echelberger C, Poplack DG: Improved treatment results in the management of single and multiple relapses of acute lymphoblastic leukemia. Cancer 45:3090-3094, 1980.
2. Buchanan GR, Rivera GK, Boyett JM, Chauvenet AR, Crist WM, Vietti TJ: Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: A Pediatric Oncology Group Study. Blood 72:1286-1292, 1988.
3. Rivera GK, Buchanan G, Boyett JM, Camitta B, Ochs J, Kalwinsky D, Amylon M, Vietti TJ, Crist WM: Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse: A Pediatric Oncology Group Study. N Engl J Med 315:273-278, 1986.
4. Henze G, Fengler R, Hartmann R, Kornhuber B, Janka-Schaub G, Niethammer D, Riehm H: Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM Group. Blood 78:1166-1172, 1991.
5. Dopfer R, Henze G, Bender-Gotze C, Ebell W, Ehninger G, Friedrich W, Gadner H, Klingebiel T, Peters C, Riehm H, Suttorp M, Schmid H, Schmitz N, Siegert W, Stollmann-Gibbels B, Hartmann R, Niethammer D: Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM and CoALL protocols: Results of the German Cooperative Study. Blood 78:2780-2784, 1991.
6. Coccia PF, Strandjord SE, Warkemin PI, Cheung N-KV, Gordon EM, Novak LJ, Shina DC, Herzig RH: High-dose cytosine arabinoside and fractionated total-body irradiation. An improved preparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission. Blood 71:888-893, 1988.
7. Sanders JE, Thomas ED, Buckner ED, Doney K: Marrow transplantation for children with acute lymphoblastic leukemia in second remission. Blood 70:324-326, 1987.
8. Dinsmore R, Kirkpatrick D, Flomenberg N, Gulati S, Kapoor N, Shank B, Reid A, Groshen S, O'Reilly RJ: Allogeneic bone marrow transplantation for patients with acute lymphoblastic leukemia. Blood 62:381-388, 1983.
9. Woods WG, Nesbit ME, Ramsay NKC, Krivit W, Kim TH, Goldman A, McGlave PB, Kersey JH: Intensive therapy followed by bone marrow transplantation for patients with acute lymphocytic leukemia in second or subsequent remission: Determination of prognostic factors (A report from the University of Minnesota Bone Marrow Transplantation Team). Blood 61:1182-1189, 1983.
10. Thomas ED, Sanders JE, Flournoy N, Johnson FL, Buckner CV, Clift RA, Fefer A, Goodell BW, Storb R, Weiden PL: Marrow transplantation for patients with acute lymphoblastic leukemia: A long-term follow-up. Blood 62:1139-1141, 1983.
11. Johnson FL, Thomas ED, Clark BS, Chard RL, Hartman JR, Storb R: A comparison of marrow transplantation with chemotherapy for children with acute lymphoblastic leukemia in second or subsequent remission. N Engl J Med 305:846-851, 1981.
12. Chessells JM, Rogers DW, Leiper AD, Blacklock H, Plowman PN, Richards S, Levinsky R, Festenstein H: Bone-marrow transplantation has a limited role in prolonging second marrow remission in childhood lymphoblastic leukaemia. Lancet 1:1239-1241, 1986.
13. Pinkel D: Bone marrow transplantation in children. J Pediatr 122:331-341, 1993.
14. Butturini A, Rivera GK, Bortin MM, Gale RP: Which treatment for childhood acute lymphoblastic leukaemia in second remission? Lancet 1:429-432, 1987.
15. Uderzo C, Valsecchi MG, Bacigalupo AM, Meloni G, Messina C, Polchi P, Di Girolamo G, Dini G, Miniero R, Locatelli F, Colella R, Tamaro P, LoCurto M, Di Tullio MT, Masera G: Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: Ten-year experience of the Italian Bone Marrow Transplant Group and the Italian Pediatric Hematology Oncology Association. J Clin Oncol 13:352-358, 1995.
16. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andrief M, Kolitz J, Gabrilore J, Reich L, Mayer K, Keefe D, Trainor K, Schluger A, Penenberg D, Raymond V, O'Reilly R, Jhanwar S, Young C, Clarkson B: Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77:1666-1674, 1991.
17. Wiernik PH, Banks PLC, Case DC, Zalman AA, Periman PO, Todd MB, Ritch PS, Enck RE, Weittberg AB: Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79:313-319, 1992.
18. Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, Gerber MC, Banks PK: A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group Study. J Clin Oncol 10:1103-1111, 1992.
19. Tan CTC, Hancock C, Steinherz P, Bacha DM, Steinherz L, Luks E, Winick N, Meyers P, Mendora A, Dantis E, Neidzwiecki D, Stevens Y-W: Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer. Cancer Res 47:2990-2995, 1987.
20. Feig SA, Krailo MD, Harris RE, Baum E, Holcenberg JS, Kaizer H, Steinherz L, Pendergrass TW, Saunders EF, Warkentin PL, Bleyer WA, Hammond GD: Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: A report from the Childrens Cancer Study Group. Med Pediatr Oncol 20:124-129, 1992.
21. Arcamone F, Bernardi L, Giardino P, Patelli B, DiMarco A, Casazza AM, Pratesi G, Reggiani P: Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin and their β-anomers. Cancer Treat Rep 60:829-834, 1976.
22. DiMarco A, Casazza A, Soranzo C, Pratesi G: Effect of various substitutions in positions 1,2,3, and 4 of 4-demethoxydaunorubicin and 4-demethoxyadriamycin. Cancer Chemother Pharamcol 1:249-254, 1978.
23. Casazza AM, Pratesi G, Guiliani F, DiMarco A: Antileukemic activity of 4-demethoxydaunorubicin in mice. Tumori 66:549-564, 1980.
24. Reid JM, Pendergrass TW, Krailo M, Hammond GD, Ames MM: Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients. A Childrens Cancer Study Group Report. Cancer Res 50:6525-6528, 1990.
25. Pannuti F, Camaggi CM, Strocchi E, Comparsi R, Angetelli B, Pacciarini MA: Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. Cancer Chemother Pharmacol 16:295-299, 1986.
26. Bellini O, Tosana MG, Bertazzoli C: Comparison of the cardiotoxicity of anthracyclines in two experimental models in mice. Drugs Exp Clin Res 10:91-95, 1984.
27. Casazza AM, DiMarco A, Bonadonna G, Bonafante V, Bartazzoli C, Bellini O, Pratesi G, Sala L, Ballerini L: Effects of modifications in position 4 of the chromophore or in position 4′ of the aminosugar, on the antitumor activity and toxicity of daunorubicin and doxorubicin. In Crooke ST, Reich SD (eds): "Anthracyclines: Current Status and New Developments." New York: Academic Press, 1980, pp 403-430.
28. Bleyer WA: Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep 61:1419-1425, 1977.
29. Capizzi RL: Improvement in the therapeutic index of methotrexate (MSC-740) by L-asparaginase (MSC-109229). Cancer Chemother Rep 6(3):37-41, 1975.
30. Rudnick SA, Cadman EC, Capizzi RL, Skeel RT, Bertino JR, McIntosh S: High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer 44:1189-1193, 1979.
31. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958.
32. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966.
33. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1-39, 1977.
34. Breslow N: Comparison of survival curves. In Buyse M, Staquet M, Sylvester M (eds): "Cancer Clinical Trials: Methods and Practice." Oxford: Oxford University Press, 1988, pp 381-406.
35. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972.
36. Breslow N: Analysis of survival data under the proportional hazards model. Int Stat Rev 43:45-58, 1975.
37. Bernstein L, Anderson J, Pike MC: Estimation of the proportional hazard in two-treatment group clinical trials. Biometrics 37:513-519, 1981.
38. Aur RJA, Simone J, Hutsu HO, Walters T, Barella L, Pratt C, Pinkel D: Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. Blood 37:272-281, 1971.
39. Reihm H, Langermann HJ, Gadner H, Odenwald E, Henze G: The Berlin Childhood Acute Lymphoblastic Leukemia Therapy Study, 1970-1976. Am J Pediatr Hematol/Oncol 2:299-306, 1980.
40. Gaynon PS, Steinherz PG, Bleyer WA, Ablin AR, Albo VC, Finklestein JZ, Grossman NJ, Littman PS, Novak LT, Pyesmany AF, Reaman GH, Sather HN, Hammond GD: Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features: Early conclusions of study CCG-106 by the Childrens Cancer Study Group. Lancet 2:921-924, 1988.
41. Ross D, Tong Y, Comblatt B: Idarubicin (IDA) is less vulnerable to transport-mediated multi-drug resistance (MDR) than its metabolite idarubicinol (IDAol) or daunorubicin (DNR). Blood 82(Suppl 1):257a, 1993.
42. Berman E, McBride M: Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 79:3267-3273, 1992.
43. Kuffel MJ, Reid JM, Ames MM: Anthracyclines and their C-13 alcohol metabolites: Growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol 30:51-57, 1992.